SciCombinator

Discover the most talked about and latest scientific content & concepts.

ML Torre, E Lucarelli, S Guidi, M Ferrari, G Alessandri, L de Girolamo, A Pessina and I Ferrero
Abstract
Mesenchymal Stromal Cells (MSC), as advanced therapy products, must satisfy all the requirements for human use of medicinal products, aiming to maintain the quality and safety of the cells. The MSC manufacturing process for clinical use should comply with the principles of Good Manufacturing Practice (GMP). This ensures that cell preparations are produced and controlled, from the collection and manipulation of raw materials, through the processing of intermediate products, to the quality controls, storage, labelling and packaging, and release. The objective of this document is to provide the minimal quality requirements for the MSC production and its delivery for clinical use, so the safety of the final cell therapy product will not be compromised. For this purpose, the document evaluates the most important steps of GMP-compliant MSC production: the isolation and expansion process; the validation phase of the process, including all quality controls for the characterization, functionality, potency and safety of MSCs; the quality control at the batch release to guarantee the safety of patient infusion. This opinion paper reflects the consensus viewpoint of the authors and scientists participating the GISM Working Group*. * GISM Working Group includes the following individual investigators: Biagi E, Del Bue M, Frigerio S, Lisini D, Marazzi M, Mareschi K, Nava S, Parolini O, Riccobon A, Romagnoli L, ViganĂ² M.
Tweets*
0
Facebook likes*
0
Reddit*
0
News coverage*
0
Blogs*
1
SC clicks
1
Concepts
Management, Production and manufacturing, Stroma of ovary, Stroma, Quality control, Stromal cell, Stem cell, Mesenchymal stem cell
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com